Equities

BibbInstruments AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

BibbInstruments AB

Actions
  • Price (EUR)0.1905
  • Today's Change-0.004 / -2.06%
  • Shares traded--
  • 1 Year change+3.53%
  • Beta0.4162
Data delayed at least 15 minutes, as of Feb 11 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BibbInstruments AB is a Sweden-based medical technology company. It develops and sales biopsy instruments, which are based on technology platform EndoDrill. The drill function enables early cancer diagnosis, especially in deep skin tissues. The portfolio includes EndoDrill GI Upper for stomach biopsy, EndoDrill GI Lower for intestinal biopsy, EndoDrill GI Lung for lung biopsy, EndoDrill Therapy to pass displacements in different organs for placement of conductors, balloons and stents for treatment, EndoDrill Needle for breasts biopsy, as well as EndoDrill Model X for multiple areas and falls under independent research project. Products are distributed to hospitals with endoscopy specialists’ centers and surgical wards. The Company’s primary distribution focus is Scandinavian countries.

  • Revenue in SEK (TTM)149.00k
  • Net income in SEK-13.30m
  • Incorporated2013
  • Employees4.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.